 CAMBRIDGE, Mass., Sept. 07, 2021 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ:MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced that members of management will present at three upcoming investor conferences. Details are as follows: 